Phanstiel S. Louise 4

What Happened

• Director Phanstiel S. Louise acquired a total of 104,507 shares of Myriad Genetics, Inc. (MYGN) in open-market purchases (transaction code P) on Feb 25–27, 2026.
  • Feb 25, 2026: 6,100 shares @ $4.74 each — $28,890
  • Feb 26, 2026: 50,407 shares @ $4.80 each — $242,105
  • Feb 27, 2026: 48,000 shares @ $4.66 each — $223,728
• Total purchased ≈ 104,507 shares for about $494,723. These are purchases (insider buying), not sales or option exercises.

Key Details

• Transaction dates and reported prices: Feb 25–27, 2026; prices shown are weighted averages.
  • Footnote F1: Feb 25 purchases were multiple trades at $4.725–$4.75.
  • Footnote F2: Feb 26 purchases were multiple trades at $4.71–$5.01.
  • Footnote F3: Feb 27 purchases were multiple trades at $4.51–$4.79.
• Shares owned after transaction: not provided in the summary data here — see the full Form 4 for post-transaction holdings.
• Filing timeliness: Form 4 was filed Feb 27, 2026 (period of report begins Feb 25); this appears to be filed within the standard 2-business-day window.
• No option exercises, awards, gifts, or tax-withholding components reported — these were straight open-market purchases.

Context

• Open-market purchases are direct buys of company stock by an insider; they show personal buying activity but do not by themselves prove future performance. For full details and exact per-lot prices, consult the complete Form 4 filing (accession 0001471518-26-000002).